Allogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase Inhibitors.
Ana M MeteloAgnieszka JozwikLe Anh LuongDelaney Dominey-FoyCharlotte GrahamCharlotte AttwoodShafqat InamAlan DunlopKaty SanchezKirsty CuthillCarmel RiceMatthew StreetlyTrevor BentleyBijan BoldajipourCesar SommerBarbra Johnson SasuReuben BenjaminPublished in: Cancer research communications (2022)
Multiple myeloma is an incurable cancer of the plasma cells. A new therapy with anti-BCMA CAR T cells - the patient's own T cells genetically engineered to find and kill myeloma cancer cells - has shown encouraging results. Unfortunately, patients still relapse. In this study, we propose to use T cells from HD volunteers, which have a stronger T-cell fitness, higher cancer killing capacity, and are ready to be administered when needed.
Keyphrases
- multiple myeloma
- papillary thyroid
- newly diagnosed
- end stage renal disease
- squamous cell
- induced apoptosis
- chronic kidney disease
- bone marrow
- case report
- peritoneal dialysis
- childhood cancer
- cell proliferation
- mesenchymal stem cells
- cell therapy
- endoplasmic reticulum stress
- young adults
- free survival
- patient reported